Serina Therapeutics

Serina Therapeutics, Inc., founded in 2006, specializes in developing advanced drug delivery systems using proprietary polymer technology. The company focuses on creating novel drug conjugates that improve the efficacy and safety of treatments for conditions such as cancer, pain, refractory epilepsy, and movement disorders like Parkinson's disease and restless leg syndrome. Serina Therapeutics operates in the pharmaceutical and biotechnology markets, serving clients ranging from research institutions to pharmaceutical companies. The business model revolves around the development, licensing, and commercialization of its proprietary polymer technology, known as poly(2-oxazoline) or POZ. This technology offers a more versatile and effective alternative to traditional PEGylation, enhancing drug solubility, stability, and delivery. Revenue is generated through partnerships, licensing agreements, and the commercialization of its drug delivery platforms. The company leverages its extensive expertise in drug delivery, research, clinical development, and commercialization to bring innovative therapies to market. Keywords: polymer technology, drug delivery, cancer treatment, pain management, epilepsy therapy, movement disorders, POZ, biotechnology, pharmaceutical partnerships, clinical development.